Celgene (CELG +2.8%) gains on an upgrade to Buy on valuation at Argus, citing the company's...

|About: Celgene Corporation (CELG)|By:, SA News Editor

Celgene (CELG +2.8%) gains on an upgrade to Buy on valuation at Argus, citing the company's reiterated guidance following the Revlimid setback.